about
Non-steroid agents for idiopathic pulmonary fibrosisIPF clinical trial design and endpointsRupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodentsTranslational bioinformatics in the era of real-time biomedical, health care and wellness data streamsAssociation of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trialsIdiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrityAdvances in the management of idiopathic pulmonary fibrosis.Grape seed pro-anthocyanidins ameliorates radiation-induced lung injury.Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principleMicroRNAs and the regulation of fibrosis.Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisNew therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signalling pathway.Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice.Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice.Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosisThe clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts.Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in ratsProstaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread.Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosisThe future of the development of medicines in idiopathic pulmonary fibrosis.Smoking and idiopathic pulmonary fibrosismiR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.Long Term Culture of the A549 Cancer Cell Line Promotes Multilamellar Body Formation and Differentiation towards an Alveolar Type II Pneumocyte Phenotype.Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique.Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosisA review of current and novel therapies for idiopathic pulmonary fibrosisMacrophage heterogeneity in respiratory diseases.Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantationInterleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells.Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosisMolecular magnetic resonance imaging of pulmonary fibrosis in miceActivation of Toll-like receptor 9 attenuates unilateral ureteral obstruction-induced renal fibrosismiR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis.Investigational approaches to therapies for idiopathic pulmonary fibrosis.
P2860
Q24235478-213EB2A0-A9F8-4870-98AF-C4CA9E04FD13Q26995648-50FF6C65-A3FD-44FF-94FC-C891F32327DEQ27311403-F7A88426-82FA-405F-B781-AF35910D64CCQ28583313-E7AE459A-5E85-4588-9A14-641B12947A1BQ30359367-41ACD7D4-A42B-4B68-953C-1FA12E0BAAE1Q33738724-C4C7C2B0-DF94-4A88-94A4-2BD60A692799Q33738971-7D986389-4164-44FE-8366-1CEF206F7353Q33814226-50F0AE45-66E9-4963-AA05-1D510B2FED82Q34011439-472A20AC-F802-4354-A113-7893C16D4430Q34040907-ED616458-1E8B-4F55-9B4A-B8723D4977E7Q34238322-4429A9BE-AC08-46FC-BBE5-A0217D89073AQ34299791-80DCA53E-7452-4203-B928-FD01F8B5F149Q34432217-D963F4E5-CDA5-4284-BC9E-ED42DF0240CEQ34473644-B89D9D46-1395-4027-B755-F4DB897FC3D3Q35049443-719A4D19-97A4-46D6-97D5-F5546A3182FDQ35064880-8E1EF777-F02C-44D8-B542-C75B52E8FC16Q35144563-76888865-276D-4BDE-9A31-2F127BEF6E75Q35169475-BED0D94B-71F9-418D-9508-E26FAA5759E9Q35177613-BF256195-1DFB-4D62-95E7-B081A9B10F77Q35207651-E0BB178C-4630-4F84-9B26-01C6D7630CE1Q35274466-D7582FED-A063-4CA3-B12D-9123C60EECACQ35388266-529C540C-9CDA-41BF-9A0D-570501C93E38Q35543612-A82D6547-C92C-4D6A-B20D-491BF80C4954Q35561400-2A1488A1-675E-4E7E-94E2-8F31DF776D94Q35695573-ABC53699-5B42-4BC2-BE03-A4ED421C1DDDQ35785682-CDFFABF2-0406-4BF2-B508-3F9616581794Q35788811-6BB0E778-99DB-42C8-B1B4-8AE6441A6311Q36014083-59C1F616-5ED9-4CAC-BBDB-967DCA34513FQ36177159-4A2B51F7-FC23-4936-9445-1841C7715019Q36254194-1A402ACE-CE61-4FF6-A8A5-9810EC374C69Q36289509-FF270DF3-DB3D-49DE-BAFF-D1AD2BF3AF39Q36542274-297290D7-EAB5-409C-9EED-C2413D1A7BA3Q36692041-AD6EAA8B-72F7-4CAD-942D-6095C37869F6Q36826817-898EA210-4BD2-4844-8473-18636413134AQ36892083-31C5F84C-953E-4961-A2DF-2780FAA07518Q37596106-5305C3FC-B708-4A86-A0A8-B6A0EA56283FQ37596487-3EA42A17-2D47-4860-AF5A-318DC537C3A8Q37729185-E8CFA852-4A72-42C6-BB71-FF028604EFCBQ37729301-56E740D8-A829-48B0-8CAC-CA10B027AC0DQ37742646-D592F6FD-5536-46EA-B750-8731A44DB9E3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Strategies for treating idiopathic pulmonary fibrosis.
@en
Strategies for treating idiopathic pulmonary fibrosis.
@nl
type
label
Strategies for treating idiopathic pulmonary fibrosis.
@en
Strategies for treating idiopathic pulmonary fibrosis.
@nl
prefLabel
Strategies for treating idiopathic pulmonary fibrosis.
@en
Strategies for treating idiopathic pulmonary fibrosis.
@nl
P356
P1476
Strategies for treating idiopathic pulmonary fibrosis.
@en
P2093
R M du Bois
P2888
P304
P356
10.1038/NRD2958
P577
2010-01-22T00:00:00Z